Pioneer Group, a specialist in life science infrastructure and venture building, has teamed up with global healthcare company Novo Nordisk to launch a Golden Ticket designed to help accelerate innovations in cardiometabolic diseases, rare blood and rare endocrine disorders.
The Golden Ticket programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines in cardiometabolic disease, with robust research plans and potential for successful research development.
Pioneer Group and Novo Nordisk want to hear from science and technology founders as well as innovators from established businesses who are creating approaches for cardiometabolic disease in the following areas:
- Diabetes – Efficacy beyond blood glucose lowering, restoring insulin resistance, and regenerating & disease modifications
- Obesity – Enhancing energy expenditure, modulating hedonic eating behaviour, and modulating counter-regulatory mechanism
- Cardiovascular Disease – Atherosclerosis beyond low density lipoprotein (LDL) and triglycerides (TG) lowering, precision-medicine heart failure, disease-modification for heart failure and cardiomyopathy, and resistant hypertension & unstable angina
- Metabolic Disease Co-morbidities & Rare Disease – Metabolic dysfunction associated steatohepatitis (MASH), chronic kidney disease, rare, non-malignant haematology conditions, and rare endocrine disorders
- Drug Discovery & Enabling Technology – Drug discovery & enabling technology in the previous stated therapeutic areas
The winning company will receive: - 12-month rent-free incubation space at one of the following Pioneer locations: Victoria House London, Cherrywood Campus Dublin, BioCity Glasgow or BioCity Nottingham
- Access to Pioneer’s Venture Programmes, as well as its ecosystem and annual Investment Showcase event.
- Mentoring and support from Pioneer’s Expert Network and specialist business coaches
- Mentoring and support from Novo Nordisk’s drug discovery and development experts
As the fourth Golden Ticket programme run by Pioneer Group, the partnership with Novo Nordisk follows previous programmes formed through collaborations with CPI, AbbVie, and Astellas.
Ayokunmi Ajetunmobi, Head of Ventures at Pioneer Group, comments: “We are delighted to launch this partnership with Novo Nordisk, which provides a fantastic opportunity for science and technology founders. With the combined benefit of Pioneer’s cutting-edge facilities, support networks and resources, as well as Novo Nordisk’s expertise in cardiometabolic disease drug discovery and development, this Golden Ticket programme has the potential to significantly advance breakthrough therapies for the benefit of patients globally.”
Owing to the high level of spin-out activity in the UK, Novo Nordisk has chosen to partner with Pioneer to deliver the programme in the UK. Daniel B. Timmermann, VP of Innovation Outreach at Novo Nordisk adds: “The UK is home to several world-leading universities, harbours a strong entrepreneurial culture and a robust investor community. These elements together form the foundation for a life science entrepreneurship ecosystem where breakthrough medicines of the future are likely to be discovered. We are excited to engage with the UK start-up/early
biotech community in close partnership Pioneer Group, in our pursuit of novel therapies for people living with cardiometabolic diseases.”
Entries to the Golden Ticket competition will close on 15 November 2024. All entries will be reviewed by the Pioneer and Novo Nordisk selection committee, and shortlisted candidates will be invited to a virtual pitching event. The Golden Ticket winner will be announced during the first week of December, with the potential for the winner to move into their chosen incubator space in January
2025.
